Major prognostic factors are: the age at diagnosis (better prognosis if younger than 18 months), the tumor stage (according to the International Neuroblastoma Staging System (INSS)[4] or the International Neuroblastoma Risk Grouping Staging System (INRGSS)[5]), the pathology based on the International Neuroblastoma Pathology Classification (INPC)[6–8], various biological factors [3], and somatic genetic abnormalities, especially the amplification of the MYCN oncogene, which occurs in 20 to 25% of NBs[9]. Here, MYCN is linked to neuroblastoma.